During the past decade, Abgenix conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Abgenix" #1 collaborator was "National Cancer Institute (NCI)" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Abgenix" are "Bronchitis, Chronic" (1 trials), "Lung Cancer" (1 trials) and "Pulmonary Disease, Chronic Obstructive" (1 trials). Many other conditions were trialed in "Abgenix" in a lesser frequency.

Most popular intervention types in "Abgenix" are "Biological" (1 trials), "Drug" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "ABX-IL8" (1 trials), "monoclonal antibody 11D10 anti-idiotype vaccine" (1 trials), "monoclonal antibody 3H1 anti-idiotype vaccine" (1 trials) and "radiation therapy" (1 trials). Other intervention names were less common.

The vast majority of trials in "Abgenix" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Abgenix". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Abgenix, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Abgenix, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".